人民财讯1月26日电，广济药业（000952）1月26日发布业绩预告，预计2025年亏损3.99亿元—5.18亿 元，上年同期亏损2.95亿元。报告期内，受行业市场竞争持续加剧影响，公司主要产品销售价格长期处 于低位，未能呈现回暖态势；部分控股子公司经营状况未能得到有效改善，持续出现亏损。 ...

格隆汇1月26日丨广济药业（维权）(000952.SZ)公布，预计2025年归属于上市公司股东的净利润-51,800 万元～-39,900万元，上年同期-29,529.11万元；扣除非经常性损益后的净利润-52,750万元～-40,850万 元。1、报告期内，受行业市场竞争持续加剧影响，公司主要产品销售价格长期处于低位，未能呈现回 暖态势。在此背景下，公司产能利用率及整体经营业绩均未达预期，导致公司报告期内仍处于经营性亏 损状态。2、报告期内，公司部分控股子公司经营状况未能得到有效改善，持续出现亏损。同时，受产 线开工率不足、产品市场价格下行等多重不利因素叠加影响，相关资产已出现明显的减值迹象。基于谨 慎性原则，依据《企业会计准则》的相关规定，公司对存在减值迹象的资产计提了相应的减值准备。最 终减值金额将由公司聘请的评估机构及会计师事务所进行专业评估和审计后确定，并以正式出具的评估 及审计报告为准。 ...

每经AI快讯，广济药业1月26日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润为-5.18亿 元至-3.99亿元，基本每股收益-1.4872元~-1.1456元。业绩变动主要原因是，报告期内，受行业市场竞争 持续加剧影响，公司主要产品销售价格长期处于低位，未能呈现回暖态势。在此背景下，公司产能利用 率及整体经营业绩均未达预期，导致公司报告期内仍处于经营性亏损状态。报告期内，公司部分控股子 公司经营状况未能得到有效改善，持续出现亏损。同时，受产线开工率不足、产品市场价格下行等多重 不利因素叠加影响，相关资产已出现明显的减值迹象。基于谨慎性原则，公司对存在减值迹象的资产计 提了相应的减值准备。最终减值金额将由公司聘请的评估机构及会计师事务所进行专业评估和审计后确 定，并以正式出具的评估及审计报告为准。 （记者 王晓波） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...

格隆汇1月26日丨广济药业(000952.SZ)公布，预计2025年归属于上市公司股东的净利润-51,800万元 ～-39,900万元，上年同期-29,529.11万元；扣除非经常性损益后的净利润-52,750万元～-40,850万元。 1、报告期内，受行业市场竞争持续加剧影响，公司主要产品销售价格长期处于低位，未能呈现回暖态 势。在此背景下，公司产能利用率及整体经营业绩均未达预期，导致公司报告期内仍处于经营性亏损状 态。2、报告期内，公司部分控股子公司经营状况未能得到有效改善，持续出现亏损。同时，受产线开 工率不足、产品市场价格下行等多重不利因素叠加影响，相关资产已出现明显的减值迹象。基于谨慎性 原则，依据《企业会计准则》的相关规定，公司对存在减值迹象的资产计提了相应的减值准备。最终减 值金额将由公司聘请的评估机构及会计师事务所进行专业评估和审计后确定，并以正式出具的评估及审 计报告为准。 ...

广济药业公告，预计2025年度归母净利润亏损5.18亿元至3.99亿元，上年同期为亏损2.95亿元。报告期 内，受行业市场竞争持续加剧影响，公司主要产品销售价格长期处于低位，未能呈现回暖态势。在此背 景下，公司产能利用率及整体经营业绩均未达预期，导致公司报告期内仍处于经营性亏损状态。 ...

证券代码：000952 证券简称：广济药业 公告编号：2026-008 湖北广济药业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 公司本次业绩预告相关数据未经注册会计师审计，但公司就业绩预告有关 事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本次业绩 预告方面不存在重大分歧。 三、业绩变动原因说明 1、报告期内，受行业市场竞争持续加剧影响，公司主要产品销售价格长 期处于低位，未能呈现回暖态势。在此背景下，公司产能利用率及整体经营业 绩均未达预期，导致公司报告期内仍处于经营性亏损状态。 2、报告期内，公司部分控股子公司经营状况未能得到有效改善，持续出 现亏损。同时，受产线开工率不足、产品市场价格下行等多重不利因素叠加影 响，相关资产已出现明显的减值迹象。基于谨慎性原则，依据《企业会计准则》 的相关规定，公司对存在减值迹象的资产计提了相应的减值准备。最终减值金 额将由公司聘请的评估机构及会计师事务所进行专业评估和审计后确定，并以 正式出具的评估及审计报告为准。 四、风险提示 1、业绩预告期 ...

Core Viewpoint - The article discusses the legal proceedings against Guangji Pharmaceutical due to financial reporting irregularities, which have led to investor losses and the opportunity for affected investors to seek compensation through legal channels [1][2][3]. Group 1: Legal Proceedings - A new batch of cases has been submitted to the court by the Liu Peng lawyer team from Shanghai Huzhi Law Firm, currently gathering affected investors [1][2]. - The case was initiated after Guangji Pharmaceutical received an administrative penalty decision from the Hubei regulatory authority on July 22, indicating issues with the company's financial reports [1][2]. Group 2: Financial Reporting Irregularities - Guangji Pharmaceutical's subsidiary, Hubei Guangji Pharmaceutical Jikang, reported inflated revenues by using the gross method instead of the net method for revenue recognition, leading to overstatements of 45.60 million yuan, 136.86 million yuan, and 138.20 million yuan for the first quarter, half-year, and third quarter of 2022, respectively, which accounted for 25.49%, 26.68%, and 20.49% of the reported revenues for those periods [3]. - The company issued a correction announcement in April 2023, acknowledging the accounting errors for the first three quarters of 2022, which were deemed violations of the Securities Law by the Hubei Securities Regulatory Bureau [2][3]. Group 3: Compensation Eligibility - Investors who purchased shares between March 25, 2022, and April 20, 2023, and sold or held them after April 21, 2023, at a loss are eligible to participate in the compensation claims, with a deadline for claims set for April 20, 2026 [3].

Core Viewpoint - Guangji Pharmaceutical is facing financial pressure as it seeks large external financing while simultaneously reducing internal capital through a registered capital reduction of RMB 22 million for its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute [1][3] Group 1: Capital Reduction and Strategic Planning - The company announced a reduction in registered capital for its subsidiary, decreasing it from RMB 50 million to RMB 28 million, aimed at optimizing asset structure and improving asset management efficiency [2][1] - The decision for capital reduction is based on the company's strategic planning and actual operational needs [2] Group 2: Financial Performance and Losses - Guangji Pharmaceutical reported a net loss of RMB 140 million in 2023, which is expected to increase to RMB 295 million in 2024, representing a year-on-year decline of 110.55% with total revenue dropping by 13.42% to RMB 639 million [4] - The company’s core product line, particularly the formulation series, has seen a significant decline, with revenue dropping by 65.26% in 2024 [4] - The financial structure has worsened, with total assets of RMB 2.58 billion and liabilities of RMB 1.62 billion, resulting in a debt-to-asset ratio of 62.67% as of Q3 2025 [5] Group 3: Regulatory Issues and Penalties - The company is also facing regulatory penalties due to information disclosure violations, resulting in a total fine of RMB 3.1 million imposed by the Hubei Securities Regulatory Bureau [6][7] - The violations involved misreporting revenue by using the gross method instead of the net method, leading to inflated revenue figures in multiple financial reports [7] Group 4: Future Outlook and Challenges - The company is attempting to enhance the competitiveness of its main products and improve asset management to reduce losses, but the path to recovery remains uncertain [7] - Questions remain regarding the specific use of funds from the capital reduction and whether the trend of reduced losses can be sustained moving forward [7]

Group 1 - The company held its 14th (temporary) meeting of the 11th Board of Directors on January 9, 2026, to discuss several key resolutions [1][4][61] - The board approved the repurchase and cancellation of 119,700 restricted stocks from five former employees who no longer meet the incentive conditions of the 2021 stock incentive plan [1][28][40] - The board also approved the nomination of Liu Wei as an independent director candidate, who will serve as the chair of the audit committee and a member of the remuneration and assessment committee [5][49] Group 2 - The board approved the revision and establishment of several governance systems to enhance operational standards and comply with relevant laws and regulations [8][53] - The company plans to reduce the registered capital of its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute, by 22 million yuan, bringing the total registered capital down to 28 million yuan [55][59] - The company applied for a comprehensive credit line of 230 million yuan from Zheshang Bank, which includes a general credit limit of 130 million yuan and a low-risk credit limit of 100 million yuan [61][62] Group 3 - The company will hold its first temporary shareholders' meeting of 2026 on January 27, 2026, to discuss the approved resolutions [21][67] - The meeting will include both on-site and online voting options for shareholders [68][75] - The company ensures that all resolutions comply with the relevant laws and regulations, and the independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange [50][71]

Group 1 - The company announced the approval of multiple resolutions during the 14th (temporary) meeting of the 11th Board of Directors, including the proposal to repurchase and cancel part of the restricted stock from the 2021 incentive plan [2] - The company also approved the proposal for the supplementary election of an independent director [2] - Additionally, the company passed resolutions to revise and establish certain governance systems [2]